Analysts expect BioXcel Therapeutics, Inc. to report revenue of 183,626.26 for Q3 26, against a range of 168,943.69 to 198,308.83. The most recent reported quarter, Q2 26, came in at 182,000.00, a 63.9% miss against the 504,121.82 consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 214,000.00 | 366,000.00 | 168,000.00 | 120,000.00 | 98,000.00 | 256,000.00 | 206,000.00 | 182,000.00 | - | - | - | - | - | - | - | - | ||||||||||
| High Estimate | 1.35 M | 319,356.44 | 332,578.13 | 172,902.50 | 215,734.09 | 165,620.55 | 389,280.42 | 530,594.27 | 198,308.83 | 215,251.50 | 870,287.53 | 1.28 M | 2.60 M | 3.10 M | 14.02 M | 16.67 M | ||||||||||
| Low Estimate | 1.25 M | 277,498.42 | 308,239.87 | 154,895.26 | 189,245.97 | 151,080.49 | 332,975.52 | 477,649.37 | 168,943.69 | 185,591.14 | 767,424.47 | 1.16 M | 2.23 M | 2.75 M | 12.12 M | 15.40 M | ||||||||||
| Consensus Estimate | 1.30 M | 298,427.43 | 320,409.00 | 163,898.88 | 202,490.03 | 158,350.52 | 361,127.97 | 504,121.82 | 183,626.26 | 200,421.32 | 818,856.00 | 1.22 M | 2.42 M | 2.93 M | 13.07 M | 16.03 M |
Analysts expect BioXcel Therapeutics, Inc. to report earnings per share of -0.96 for Q3 26, against a range of -1.02 to -0.90. The most recent reported quarter, Q2 26, came in at -0.49, a 15.6% miss against the -0.42 consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -5.12 | -3.57 | -1.50 | -2.45 | -2.18 | -0.58 | -0.54 | -0.49 | - | - | - | - | - | - | - | - | ||||||||||
| High Estimate | -7.90 | -5.48 | -2.81 | -1.67 | -1.17 | -0.55 | -0.51 | -0.40 | -0.90 | -0.66 | -0.29 | -0.27 | -0.29 | 0.29 | -0.28 | -0.47 | ||||||||||
| Low Estimate | -9.34 | -6.20 | -3.01 | -1.95 | -1.39 | -0.65 | -0.59 | -0.44 | -1.02 | -0.74 | -0.31 | -0.29 | -0.33 | 0.25 | -0.30 | -0.55 | ||||||||||
| Consensus Estimate | -8.62 | -5.84 | -2.91 | -1.81 | -1.28 | -0.60 | -0.55 | -0.42 | -0.96 | -0.70 | -0.30 | -0.28 | -0.31 | 0.27 | -0.29 | -0.51 |
Pull Wall Street consensus for BioXcel Therapeutics, Inc. (high, low and consensus estimates alongside reported actuals) into your own models and apps with the Business Quant Estimates API. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/estimates?ticker=BTAIQ&mode=revenue&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/estimates"
params = {"ticker": "BTAIQ", "mode": "revenue", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/estimates?ticker=BTAIQ&mode=revenue&api_key=YOUR_API_KEY");
const data = await res.json();